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Summary
 
To identify novel genes that are involved in positive selection of thymocytes, we performed
polymerase chain reaction (PCR)-based subtractive hybridization between selecting and non-
selecting thymi. OT-1 T cell receptor (TCR) transgenic thymocytes on a recombination acti-
vating gene (RAG) null background are efficiently selected into the CD8 lineage in H-2
 
b
 
 mice
(RAG-2
 
2
 
/
 
2
 
OT-1, selecting thymi), but are not selected on a transporter associated with anti-
gen processing (TAP) null background (RAG-2
 
2
 
/
 
2
 
TAP-1
 
2
 
/
 
2
 
OT-1, nonselecting thymi). We
report here our studies of one gene, ITM2A, whose expression is dramatically higher in T cells
in the selecting thymus. The expression pattern of ITM2A in thymocyte subsets correlates with
upregulation during positive selection. In addition, ITM2A expression is higher in the thymus
than in either the spleen or lymph nodes, but can be upregulated in peripheral T cells upon ac-
tivation. ITM2A expression was also induced in RAG-2
 
2
 
/
 
2
 
 thymocytes in vivo upon CD3
cross-linking. We demonstrate that ITM2A is a type II membrane glycoprotein that exists as
two species with apparent M
 
r
 
 of 45 and 43 kD and appears to localize primarily to large cyto-
plasmic vesicles and the Golgi apparatus, but is also expressed on the cell surface. Expression on
the surface of EL4 cells increases with activation by phorbol myristate acetate (PMA) and iono-
mycin. Finally, overexpression of ITM2A under control of the lck proximal promoter in mice
results in partial downregulation of CD8 in CD4
 
1
 
CD8
 
1
 
 
 
double positive (DP) thymocytes, and
a corresponding increase in the number of CD4
 
1
 
CD8
 
lo
 
 thymocytes. Possible roles for this
novel activation marker in thymocyte development are discussed.
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T
 
he development of mature CD4 and CD8 T cells de-
pends upon a small percentage of immature CD4
 
1
 
CD8
 
1
 
double positive (DP)
 
1
 
 thymocytes surviving the process of
selection in the thymus. To be positively selected into the
CD4 or CD8 lineage, the DP cells must express a TCR
with intermediate affinity for self-MHC/peptide ligands. DP
cells expressing TCR with too low or too high an affinity
for the ligand undergo programmed cell death by “neglect”
or negative selection, respectively (1, 2). Positive selection
is a process that is currently characterized and monitored by
changes in a limited number of cell surface and intracellular
proteins. Hallmark changes during the first stage of selec-
tion include an upregulation of CD69 (3, 4) and CD5 (5, 6)
and a downregulation of intracellular recombination acti-
vating gene (RAG)-1 and RAG-2 (4, 7–9). A downregula-
tion of cell surface CD4 and CD8 from high to low levels
then occurs, accompanied by an upregulation of TCR/CD3
from low to intermediate levels (10–12). The subsequent
upregulation of cell surface CD4 and TCR/CD3 results in
production of the CD4
 
1
 
CD8
 
lo
 
TCR
 
int/hi
 
 intermediate cells
which are precursors for both lineages (13–15). A selective
downregulation of one coreceptor accompanied by a fur-
ther upregulation of the other coreceptor, TCR/CD3, and
intracellular bcl-2 characterizes cells that have survived se-
lection and committed to a lineage (12, 16, 17). Comple-
tion of maturation is characterized by the downregulation
of CD69 (3) and heat-stable antigen (HSA [18]) on TCR
 
hi
 
single positive (SP) cells (12).
How do all of these changes occur? Significant progress
has been made in identifying the signaling pathways and
transcription factors involved in transmitting a signal initi-
ated at the cell surface through binding of the TCR to its
ligand into changes in the transcriptional program and sur-
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid(s); BrdU, 5-bromo-
2
 
9
 
-deoxyuridine; DN, CD4
 
2
 
CD8
 
2
 
 double negative; DP, CD4
 
1
 
CD8
 
1
 
double positive; ER, endoplasmic reticulum; GAPDH, glyceraldehyde
 
3-phosphate dehydrogenase; GST, glutathione 
 
S
 
-transferase; HPRT,
hypoxanthine phosphoribosyltransferase; HSA, heat-stable antigen; RAG,
recombination activating gene; RT, reverse transcription; SP, single posi-
tive; TAP, transporter associated with antigen processing. 
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face phenotype of the developing thymocytes. However,
not all of the molecules involved in positive selection have
been identified. We have used a PCR-based method of sub-
tractive hybridization to find novel genes that are upregu-
lated or downregulated during the differentiative stages
between immature DP and mature SP thymocytes, namely,
during positive selection. To do this, we used mice expressing
a transgenic MHC class I–restricted TCR (OT-1) bred onto
a selecting (H-2
 
b
 
) recombination-deficient (RAG-2
 
2
 
/
 
2
 
)
background (19, 20) or a nonselecting RAG-2
 
2
 
/
 
2
 
 trans-
porter associated with antigen processing (TAP)-1
 
2
 
/
 
2
 
 back-
ground. Without TAP-1, peptides required for the selec-
tion of cells expressing MHC class I–restricted TCRs are
not transported into the endoplasmic reticulum (ER) and
cannot be presented (21). The RAG-2
 
2
 
/
 
2
 
OT-1 mice have
a hyperselecting thymus in which primarily CD8 T cells
develop. The RAG-2
 
2
 
/
 
2
 
TAP-1
 
2
 
/
 
2
 
OT-1 mice have a non-
selecting thymus in which thymocytes are arrested at the
DP stage of development. ITM2A was identified as a novel
gene in the immune system whose expression was dramati-
cally upregulated in T cells in a selecting thymus.
ITM2A was first cloned by Merregaert and colleagues as a
gene whose expression was upregulated in vitro during
chondro/osteogenesis of perichondrial precursor cells from
explanted prenatal condyles (22). The authors identified a
human homologue of ITM2A and two additional family
members in both mice and humans by homology searches of
the expressed sequence tag (EST) database. The three iso-
forms were predicted to be type II transmembrane proteins
and share 38–49% identity at the amino acid (aa) level, with
most of the similarity in the COOH-terminal domain.
Based on the developmentally regulated expression of
ITM2A in two different systems, we decided to study this
gene in greater detail in the immune system. We character-
ized expression of ITM2A in thymocytes and peripheral T
cells and found that (a) expression in thymocyte subsets
correlates with upregulation during positive selection, (b)
expression is lower in both spleen and lymph nodes com-
pared with thymus, but is upregulated upon activation of T
cells, and (c) expression can be induced in CD4
 
2
 
CD8
 
2
 
double negative (DN) thymocytes by signaling through
CD3. Furthermore, we have identified the ITM2A protein
and showed that it is a type II transmembrane glycoprotein
expressed in vesicles and on the cell surface. Finally, we
found that overexpression of an ITM2A transgene in mu-
rine thymocytes resulted in a partial downregulation of CD8
in the DP population of thymocytes, providing the first
functional information for this gene. ITM2A does not have
significant homology to any other gene known to be ex-
pressed in the immune system and therefore provides an
opportunity to explore the role of a novel protein in T cell
development.
 
Materials and Methods
 
Mice.
 
C57BL/6 mice were purchased from The Jackson Lab-
oratory and Taconic Farms. TAP-1
 
2
 
/
 
2
 
OT-1 mice (23) were
 
bred to RAG-2
 
2
 
/
 
2
 
 mice (19, 20), and the F
 
1
 
 progeny were inter-
bred to obtain RAG-2
 
2
 
/
 
2
 
TAP-1
 
2
 
/
 
2
 
OT-1 mice and RAG-2
 
2
 
/
 
2
 
OT-1 mice. P14 mice express a transgenic TCR specific for p33
in the context of H-2D
 
b
 
 (24). lck-ITM2A transgenic mice were
generated as follows. The NotI-SalI 1.6-kb fragment of pSPORT1-
ITM2A (22), containing the full-length ITM2A cDNA, was
cloned into the BamHI site of p1017 (25). The 7-kb
 
 
 
NotI fragment
from p1017-ITM2A was microinjected into fertilized (C57BL/6 
 
3
 
DBA2)F
 
2
 
 embryos to generate founders. Transgenic founders were
identified by PCR of genomic DNA using primers for ITM2A
(5
 
9
 
-TCATGCCCAAGAGCACCA-3
 
9
 
 and 5
 
9
 
-AGTTCTGTGG-
ATTTCACAATACAGATATCA-3
 
9
 
) and for human growth hor-
mone (hGH; 5
 
9
 
-TAGGAAGAAGCCTATATCCCAAAGG-3
 
9
 
and 5
 
9
 
-ACAGTCTCTCAAAGTCAGTGGGG-3
 
9
 
). Founders
were bred to C57BL/6 mice to establish lines. F
 
1
 
 from three
founders (AM573, AM712, and AM713) were used for the anal-
yses here.
 
Commercial Abs and Flow Cytometric Analysis.
 
The following
conjugates of mAbs were purchased from PharMingen: PE–anti-
CD4, FITC–anti-CD8
 
a
 
, biotin–anti-CD45R (B220), biotin–anti-
CD11b (Mac-1), biotin-anti–I-A
 
b 
 
(MHC II), biotin–anti-CD3
 
e
 
,
biotin–anti-CD69, biotin–anti-HSA, FITC–goat anti–mouse IgG,
and FITC–goat anti–rabbit IgG. Tricolor-streptavidin and PE–anti-
hCD2 were purchased from Caltag Laboratories. Antiactin, anti–
human c-myc, and horseradish peroxidase–conjugated goat anti–mouse
IgG and goat anti–rabbit IgG were purchased from Santa Cruz
Biotechnology, Inc. Cells were stained and analyzed by flow cy-
tometry using standard procedures. Flow cytometry was per-
formed on a FACScan™ or FACSCalibur™ (Becton Dickinson)
and analyzed using ReproMac software (TrueFacts Software) or
CellQuest software (Becton Dickinson).
 
Isolation of ITM2A by PCR-based Subtractive Hybridization.
 
Thymi
from 4–6-wk-old RAG-2
 
2
 
/
 
2
 
TAP-1
 
2
 
/
 
2
 
OT-1 or RAG-2
 
2
 
/
 
2
 
OT-1
mice were pooled, and total RNA was isolated using RNA
STAT-60 (Tel-Test, Inc.). mRNA was isolated using oligo(dT)
cellulose spin columns (Amersham Pharmacia Biotech). Double-
stranded cDNA primed by oligo(dT) was synthesized with Super-
script reverse transcriptase (GIBCO BRL) and used for suppres-
sion subtractive hybridization using the Clontech PCR Select
kit. In brief, the double-stranded cDNA was digested with RsaI,
ligated to adaptors, and subjected to two steps of subtractive hy-
bridization. PCR to amplify the difference products was per-
formed for 27 cycles, and nested PCR was performed for 12 cy-
cles. The subtractive hybridization was performed separately in two
directions: “selecting minus nonselecting” and “nonselecting minus
selecting.” PCR products were cloned into pCR2.1 (Invitrogen)
and screened further by differential hybridization. By comparing
signals from hybridization to probes generated from the two differ-
ent products of subtractive hybridization (“selecting minus non-
selecting” and “nonselecting minus selecting”), several differen-
tially expressed clones were identified. The inserts of these clones
were sequenced by PCR using the T7 primer and dye Rhodamine
reaction mix (Applied Biosystems, Inc.) and the ABI377 (Applied
Biosystems, Inc.) automated sequencer. Nonredundant and EST
databases were searched using BLAST 2.0 (26) for genes homolo-
gous to the resulting sequences.
 
Preparation of RNA Samples and Northern Blot Analysis.
 
Northern blot analysis was performed essentially as recommended
in Current Protocols in Molecular Biology (27). Total RNA was
prepared using RNA STAT-60, and mRNA was isolated from
total RNA by using a FastTrack kit (Invitrogen). For each North-
ern blot, 10 
 
m
 
g of total RNA was loaded per lane except for the
multitissue analysis (2 
 
m
 
g mRNA) and the analysis of RAG-2
 
2
 
/
 
2 
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thymocytes (8 
 
m
 
g total RNA). The probes used were fragments
of or complete cDNAs of mouse ITM2A, mouse RAG-1, mouse
TAP-1, mouse CD69, chicken glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH), mouse EF1
 
a
 
, mouse CD4, and I-A
 
b
 
(MHC II). They were radiolabeled using a random primer label-
ing kit (Boehringer Mannheim) and [
 
a
 
-
 
32
 
P]dATP (Dupont). For
the multitissue Northern blot, RNA was prepared from whole
tissues from C57BL/6 mice. For analysis of thymocytes versus
thymus stromal cells, thymocytes were dissociated from stroma
by pressing through a Nytex filter. Undissociated stromal material
was collected from inside the filter. Total RNA was isolated from
the enriched fractions. For analysis of expression in activated T cells,
C57BL/6 splenocytes were cultured at 3.0 
 
3
 
 10
 
6
 
/ml in DMEM
plus 10% FCS medium alone or supplemented with either 5 
 
m
 
g/ml
ConA (Calbiochem) or 1.2 ng/ml PMA (Sigma Chemical Co.) and
250 ng/ml ionomycin (Calbiochem). P14 splenocytes were cul-
tured at 2.3 
 
3
 
 10
 
6
 
/ml in RP10 alone (
 
2
 
p33) or together with
2.8 
 
3
 
 10
 
5
 
/ml irradiated EL4 cells loaded with p33 peptide
(
 
1
 
p33) as described (28). Total RNA was isolated from cells har-
vested at various times during activation. The RAG-2
 
2
 
/
 
2
 
 mice
were injected intraperitoneally with 150 
 
m
 
g anti-CD3
 
e
 
 (2C11)
Ab or PBS, and thymi were harvested 16 h after injection. Anal-
ysis of transgene expression was performed using total RNA from
thymus and spleen of transgenic mice and littermate controls.
 
Reverse Transcription PCR of Sorted Thymocytes, CD4 T Cells, and
CD8 T Cells.
 
CD4 SP, CD8 SP, DN, and DP thymocyte subsets
were sorted electronically on the basis of coreceptor expression, and
reverse transcription (RT)-PCR was performed in a manner similar
to that described previously (29). Threefold serial dilutions of tem-
plate were used in PCR with primers for ITM2A (described above)
or hypoxanthine phosphoribosyltransferase (HPRT) to normalize
for template amount. The reaction conditions yielding product in
the linear range were 30 cycles of 94
 
8
 
C for 1 min, 55
 
8
 
C for 1
min, and 72
 
8
 
C for 1 min. Mature CD4
 
1
 
CD8
 
2
 
 HSA
 
lo
 
 and inter-
mediate CD4
 
1
 
CD8
 
lo
 
HSA
 
hi
 
 thymocytes were isolated by three-
color electronic sorting and analyzed by RT-PCR as described
above. CD4
 
 
 
and CD8 mature T cells were isolated by immuno-
magnetic bead purification from C57BL/6 lymph nodes. Lympho-
cytes were incubated with biotinylated mAbs against CD45R,
CD11b, I-A
 
b
 
, and either CD8 or CD4, then with magnetic strepta-
vidin-coated beads (Dynal). Cells bound to Abs and beads were
removed by magnetic force. The remaining CD4
 
1
 
 and CD8
 
1
 
populations were each 
 
.
 
85% pure and 
 
.
 
99% free of contaminat-
ing CD8
 
1
 
 or CD4
 
1
 
 cells, respectively, as determined by flow cy-
tometry (data not shown). Total RNA isolated from each sorted
population was used in RT-PCR as described above.
 
Generation of Anti-ITM2A Antiserum and Immunoblot Analysis of Cell
Lysates.
 
A glutathione 
 
S
 
-transferase (GST)-ITM2A fusion pro-
tein containing the first 52 aa of ITM2A was used to immunize
New Zealand White rabbits (R and R Rabbitry). A portion of
the ITM2A cDNA was cloned into pGEX-2T, and expression
and purification of the fusion protein were performed according
to the manufacturer’s instructions (Amersham Pharmacia Bio-
tech). The antiserum was affinity purified using a Sepharose col-
umn to which the GST-ITM2A fusion protein was coupled. To
remove anti-GST Abs, the eluate was then immunoabsorbed
with GST-coupled Sepharose, and the flow-through was used for
immunoblot analysis and immunofluorescent microscopy.
Cell lysates were prepared as described (30) and quantitated by
Bradford assay (27). Deglycosylation of cell lysates with EndoH
(New England Biolabs) or 
 
N
 
-glycosidase F (Boehringer Mann-
heim) was performed according to the manufacturer’s instruc-
tions. Mock reactions were similar to the real reactions except the
 
enzymes were omitted. Equal amounts of protein in 1
 
3
 
 Laemmli
sample buffer (LSB) were loaded per lane for SDS-PAGE and
immunoblot analysis (27). Each step of the immunoblot analysis
was performed at room temperature for 1 h. Detection of sec-
ondary Abs was performed with ECL (Amersham Pharmacia
Biotech) followed by autoradiography (Eastman Kodak Co.). Af-
finity-purified anti–human c-myc and affinity-purified anti-
ITM2A antisera were used at 1:100. Antiactin was used at 1:500.
Horseradish peroxidase–conjugated secondary Abs, goat anti–
mouse IgG, and goat anti–rabbit IgG were used at 1:1,000.
 
Retrovirus-mediated Expression of an Epitope-tagged ITM2A. A 10-aa
sequence (EQKLISEEDL) from human c-myc was added to
the NH2 terminus of ITM2A by using the following primers:
59-AAAAAAAAAAGCGGCCGCATGGAACAAAAACTGAT-
CTCAGAAGAGGACCTGGTGAAGATCGCCTTCAACAC-39
and 59-AAAAAAAAAGTCGACTCACTCCTGACAGATCTT-
GGTTTCA-39 in PCR with pSPORT1-ITM2A. The PCR prod-
uct was cloned into the NotI and SalI sites in the retroviral vector
PMI (30, 31). Generation of the retrovirus, infection of cell lines
(EL4 and AKR1010), and enrichment of infected cells were per-
formed as described (30, 31). Cell populations enriched to .98%
were used for both immunofluorescent microscopy and cell lysates.
Immunofluorescent Confocal Microscopy. Immunofluorescent micros-
copy was performed essentially as described (32). In brief, cells
were spun onto poly-l-lysine–coated coverslips, fixed in 10% for-
malin-buffered saline, permeabilized in PBS with 0.2% Triton
X-100, and stained with Ab diluted in PBS plus 20% normal goat se-
rum. Primary Ab was anti-ITM2A or anti–human c-myc at 1:100.
Secondary Ab was FITC-conjugated goat anti–rabbit IgG or goat
anti–mouse IgG at 1:500. The cells were mounted and viewed by
confocal microscopy using a 1003 oil lens with an MRC-1024
system (Bio-Rad Laboratories) equipped with LaserSharp software
and mounted on an Axiovert TV microscope (Carl Zeiss, Inc.).
Biotinylation of EL4 Cell Surface Protein. EL4 cells were bio-
tinylated at 48C for 30 min using sulfo-NHS-LC-biotin (Pierce
Chemical Co.) (27). After washing the cells twice, lysates were
prepared and precleared twice by addition of 0.1 ml 50%
Sepharose 2B (Amersham Pharmacia Biotech) and incubation at
48C for 1 h followed by centrifugation. Precipitation of the bio-
tinylated protein was performed by addition of 0.05 ml 50%
streptavidin agarose (Pierce Chemical Co.) to the supernatant and
incubation at 48C for 1 h followed by centrifugation. The super-
natant is the unbound fraction. The precipitate (bound fraction)
was washed three times then resuspended in 0.05 ml 23 LSB.
Nonbiotinylated EL4 cells were treated in a similar manner except
for the initial incubation in which biotin was not included. Ap-
proximately 50% of the bound fraction and 2% of the unbound
fraction were used for SDS-PAGE and immunoblot analysis.
Results
Phenotype of Selecting and Nonselecting Thymi. To identify
genes whose expression was regulated during the develop-
ment of immature DP thymocytes to mature SP thymo-
cytes, we engineered mice which had a transgenic TCR on
either a selecting background or a nonselecting background.
RAG-22/2OT-1 mice express a single MHC class I–restricted
TCR on a selecting H-2b background. Flow cytometry
analysis of thymocytes showed that the DP cells in these
mice are efficiently selected predominantly into the CD8
lineage (Fig. 1 A). Compared with a C57BL/6 thymus, the220 A Novel T Cell Activation Marker
percentage of DP cells in a RAG-22/2OT-1 thymus is dra-
matically decreased and the percentage of intermediate
CD4loCD8lo and CD41CD8lo cells is increased. In addi-
tion, a higher percentage of thymocytes in RAG-22/2 OT-1
mice compared with C57BL/6 mice are CD3int/hi and CD691
(data not shown), suggesting that more cells in a RAG-22/2
OT-1 thymus are undergoing positive selection. Taken to-
gether, these data indicate that the thymus of a RAG-22/2
OT-1 mouse is “hyperselecting.” In contrast, RAG-22/2
TAP-12/2OT-1 mice have a nonselecting thymus. TAP-1
is required for selecting peptides to be transported into the ER
by the TAP-1/TAP-2 complex and presented by MHC
class I (21). RAG-2 is required for the productive rear-
rangement and expression of endogenous TCR (19, 20).
Due to the expression of only the OT-1 transgenic TCR and
the absence of selecting MHC–peptide complexes, there
were almost no detectable mature CD4 SP or CD8 SP cells
in the RAG-22/2TAP-12/2OT-1 thymus (Fig. 1 A). De-
velopment was blocked at the CD41CD81TCRlo stage,
with immature DP cells constituting .97% of the thymo-
cytes (Fig. 1 A, and data not shown). The striking absence
in RAG-22/2TAP-12/2OT-1 mice of both intermediate
(CD41CD8lo and CD4loCD8lo) and mature SP thymocytes
compared with the hyperselecting thymus of RAG-22/2
OT-1 mice suggested that subtractive hybridization between
these two thymi could reveal genes whose expression is reg-
ulated during positive selection.
ITM2A Is Upregulated in Thymocytes during T Cell Devel-
opment. We performed subtractive hybridization between
the RAG-22/2TAP-12/2OT-1 and RAG-22/2OT-1 thymi
to identify genes which are differentially expressed. Using
this protocol, we cloned RAG-1 and TAP-1, each from
the appropriate direction of subtraction, indicating that the
subtractive hybridization and subsequent screening were
successful. Downregulation of RAG-1 and RAG-2 is one
of the earliest signs of positive selection (4, 7–9). RAG-1
was highly expressed in the nonselecting thymus, consistent
with a negligible level of positive selection in this thymus
(Fig. 1 B). Conversely, there was only a very low level of
RAG-1 transcript in the thymus of RAG-22/2 OT-1 mice.
TAP-1 was expressed only in the RAG-22/2 OT-1 mice,
as expected. Of 127 cloned products from the subtraction in
the “selecting minus nonselecting” direction, 3 corresponded
to a fragment of the ITM2A cDNA. Northern blot analysis
confirmed that ITM2A is expressed at a much higher level
in the RAG-22/2OT-1 selecting thymus compared with
both the nonselecting thymus and the C57BL/6 thymus
(Fig. 1 C). Because whole thymi were used as the source
material for subtractive hybridization, it was important to
determine whether ITM2A was expressed in thymocytes,
stromal cells, or both. To address this question, we sepa-
rated thymocytes from stromal cells of a C57BL/6 thymus.
As shown in Fig. 2 A, the relative intensity of the signal de-
Figure 1. Identification of ITM2A as a developmentally regulated gene
in the thymus. (A) Flow cytometric analysis of thymocytes from C57BL/6,
RAG-22/2OT-1, and RAG-22/2TAP-12/2OT-1 mice. The numbers in
each quadrant are the percentage of total thymocytes. Northern blot anal-
ysis of (B) RAG-1 and TAP-1 expression in a RAG-22/2TAP-12/2OT-1
(nonselecting, NS) or RAG-22/2OT-1 (selecting, S) thymus and (C)
ITM2A in a C57BL/6 (B6), nonselecting (NS), or selecting (S) thymus.
The blot in C was probed for ITM2A, stripped, and reprobed for EF1a.
Figure 2. ITM2A expression in thymocyte subsets and peripheral T
cells. (A) Northern blot analysis of ITM2A in thymic stromal cells (S) and
thymocytes (T). The same blot was stripped and rehybridized with probes
for CD4 (thymocyte specific) and MHC class II (I-Ab) (stromal cell spe-
cific). (B and C) RT-PCR of sorted thymocyte subsets. Threefold serial
dilutions of cDNA representing total thymocytes (total) or one of several
subsets were used in PCR with primers for ITM2A. PCR amplification
of HPRT was performed to normalize for template amount. The subsets
analyzed in B were DN, DP, CD4 SP, and CD8 SP and in C were
CD41CD82HSAlo (4182HSAlo) and CD41CD8loHSAhi (418loHSAhi)
thymocytes. The same DP sample used in B was included in C as a rela-
tive standard for comparison. (D) RT-PCR of peripheral CD4 and CD8
T cells. RT-PCR was performed as in B and C on threefold serial dilu-
tions of cDNA from the purified T cells (CD4 and CD8). For the exper-
iments in B, C, and D, purity of the sorted cells was assessed by flow cy-
tometry (data not shown), and PCR was performed on material from two
different sorts with similar results.221 Kirchner and Bevan
tected from thymocytes versus stromal cells with the ITM2A
probe was similar to that seen with the CD4 probe (thy-
mocyte specific), but dissimilar to that seen with the
MHC II probe (stromal cell specific). Therefore, within the
thymus, ITM2A appears to be expressed predominantly in
thymocytes.
To determine the timing of ITM2A expression during
normal thymocyte development, we performed RT-PCR
analysis of FACS®-sorted thymocyte populations: DN, DP,
CD4 SP, and CD8 SP (Fig. 2 B). ITM2A cDNA was barely
detected in the DN population, and a low level was detected
in the DP and CD8 SP populations. ITM2A appeared to be
expressed most highly in the CD4 SP subset. Given that the
ITM2A clones came from subtractive hybridization using a
selecting thymus in which T cells develop primarily into the
CD8 lineage, the higher expression level in the CD4 SP
subset compared with the CD8 SP subset was surprising.
This could be due to inclusion in the CD4 SP sorted popu-
lation of some intermediate CD41 cells which had not fully
downregulated CD8, or alternatively there may be differen-
tial expression of ITM2A in mature CD4 and CD8 thymo-
cytes. To distinguish between these two possibilities, we
isolated mature CD41CD82HSAlo and intermediate CD41
CD8loHSAhi thymocytes and analyzed expression of ITM2A
by RT-PCR (Fig. 2 C). Interestingly, of all the subsets ex-
amined, CD41CD8loHSAhi thymocytes had the highest
level of ITM2A expression, significantly higher than CD41
CD82HSAlo thymocytes. However, the expression level in
mature CD41CD82HSAlo thymocytes was still higher than
that detected in either DP or CD8 SP sorted thymocytes.
Thus, mature CD41 thymocytes express more ITM2A than
do mature CD81 thymocytes.
To determine whether ITM2A was expressed differen-
tially in mature peripheral CD4 and CD8 T cells, we puri-
fied CD4 and CD8 T cells from C57BL/6 lymph nodes
and performed RT-PCR analysis (Fig. 2 D). The purity
of each population was assessed by flow cytometry and
RT-PCR using primers for CD4 and CD8 (data not
shown). Unlike in sorted thymocytes, ITM2A appeared to
be expressed equally in peripheral T cells of both lineages.
ITM2A Is Expressed at a Higher Level in Thymus Compared
with Spleen or Lymph Node, but Is Upregulated in Peripheral T
Cells by Signaling through the TCR. We examined expres-
sion of ITM2A in several tissues of the adult mouse by
Northern blot analysis (Fig. 3). Expression of ITM2A was
highest in thymus and skeletal muscle and lower in lymph
node and spleen. ITM2A expression was fairly widespread,
as low levels were also detected in brain, heart, lung, stom-
ach, and uterus. However, ITM2A was not detected in small
intestine, kidney, liver, or testes, even after a long exposure.
To determine if ITM2A expression was upregulated in
peripheral T cells upon activation, we examined expression
in splenocytes harvested at various time points after activa-
tion. C57BL/6 splenocytes were cultured in the presence
of the T cell mitogen, ConA (Fig. 4 A). Splenocytes from P14
mice, which express an MHC class I–restricted transgenic
TCR, were activated by antigen presentation of the cog-
nate peptide (Fig. 4 B). The blots were probed for ITM2A,
CD69, a T cell activation marker (33–36), and EF1a, a
housekeeping gene. In both experiments, the amount of
ITM2A transcript started to increase within 30 min of acti-
vation and peaked at 6 h, reaching a level similar to that in
an untreated C57BL/6 thymus. Expression was greatly re-
duced by 24 h. The kinetics of ITM2A induction in sple-
nocytes were similar to those of CD69 (Fig. 4 A, and data
not shown), but ITM2A and CD69 transcripts were present
at quite different steady state levels in the thymus. Al-
though these experiments do not exclude the possibility
that some amount of the ITM2A transcript was contributed
by non-T cells, expression of ITM2A, like CD69, was up-
regulated as a direct result of signals transmitted through
the TCR upon binding of ConA or the more physiological
MHC-peptide ligand.
ITM2A expression detected by RT-PCR was higher in
DP thymocytes compared with DN thymocytes. To see if
ITM2A could be induced in DN cells by signaling through
CD3, we examined expression in thymocytes from RAG-
Figure 3. Analysis of ITM2A expression in several tissues. 2 mg of
mRNA was loaded per lane. The blot was successively hybridized,
stripped, and rehybridized with probes for ITM2A and two housekeeping
genes, GAPDH and EF1a.
Figure 4. Northern blot analysis of activated splenocytes. (A) C57BL/6
splenocytes were cultured in medium alone (medium) or supplemented
with 5 mg/ml ConA (1ConA). (B) P14 splenocytes were cultured alone
(2p33) or in the presence of irradiated EL4 cells coated with p33 peptide
(1p33). Total RNA was extracted from cells harvested at various times
during activation and from an untreated C57BL/6 thymus (Thy). The
blots in A and B were hybridized with probes for ITM2A, EF1a, and
CD69 (shown for A only).222 A Novel T Cell Activation Marker
22/2 mice which had been treated in vivo with anti-CD3e
Ab (2C11) or PBS (Fig. 5). RAG-22/2 thymocytes consist
solely of DN cells which are unable to rearrange their
TCR genes, preventing expression of the pre-TCR (19, 20).
However, they do express low levels of CD3, and cross-
linking with anti-CD3e Ab activates the DN cells and in-
duces their differentiation into DP cells (37). Northern blot
analysis revealed that ITM2A expression was almost unde-
tectable in the control RAG-22/2 thymocytes, but was sig-
nificantly increased in thymocytes from mice injected with
anti-CD3e Ab at 16 h after stimulation, before the appear-
ance of any DP cells.
ITM2A Is a Glycoprotein That Exists as Two Species with
Apparent Mr of 45 and 43 kD. To identify the ITM2A pro-
tein, we raised Abs against a GST-ITM2A fusion protein
containing the first 52 aa of ITM2A. The polyclonal antise-
rum was affinity purified and used for immunoblot analysis
of cell lysates prepared from EL4 (a thymoma cell line
which expresses endogenous ITM2A) and from EL4 trans-
fected with an NH2-terminal myc-tagged version of ITM2A
(NmycITM2A; Fig. 6 A, left panel). A specific band corre-
sponding to an apparent Mr of 43 kD was detected with the
anti-ITM2A antiserum in both EL4 and EL41Nmyc-
ITM2A lysates, but not in the purified GST control sam-
ple. A band of this size was not detected using preimmune
serum from the same rabbit (data not shown). In identical
blots probed with anti–human c-myc Ab (anti-myc), a pro-
tein of the same size was detected only in EL41Nmyc-
ITM2A (Fig. 6 A, right panel). On close inspection, there
appeared to be an additional minor second band. Lysates
from EL4, EL41NmycITM2A, and AKR1010, a CD41
CD81 thymoma cell line which does not express ITM2A,
were analyzed using gel conditions with greater resolution
(Fig. 6 B). Two species were detected with anti-ITM2A
antiserum in both EL4 and EL41NmycITM2A, but not in
AKR1010. The two species of ITM2A had apparent rela-
tive Mr of 45 and 43 kD, the smaller of which was pre-
dominant. Upon stripping and reprobing the blot with
anti-myc Ab, two species of identical size were detected in
the EL41NmycITM2A sample, but not in either EL4 or
AKR1010 (data not shown).
ITM2A had been predicted to be a 263-aa type II integral
membrane protein with a 52-aa NH2-terminal domain, a
23-aa transmembrane domain, and a 188-aa COOH-termi-
nal domain (22). The observed sizes of the two species de-
tected with anti-ITM2A antiserum (45 and 43 kD) were sig-
nificantly larger than the predicted size for ITM2A (30 kD),
possibly due to posttranslational modification. A single puta-
tive N-linked glycosylation site had been predicted at aa
position 166 (within the COOH-terminal extracellular do-
main [22]). To determine if ITM2A had N-linked glycosyla-
tion, we treated the EL4 cell lysate with either EndoH or
N-glycosidase F and analyzed the digested proteins by
SDS-PAGE and immunoblot analysis (Fig. 6 C). Treatment
with EndoH resulted in increased mobility of a fraction of
the ITM2A protein. The smaller species had an apparent
Mr of 39 kD. It was not possible to discern from which of
the two larger species it was derived. The amount of the
39-kD species formed by EndoH digestion is likely to re-
flect the amount of ITM2A protein in the ER. Digestion
with N-glycosidase F resulted in a complete conversion of
the two larger species of ITM2A to the smaller 39-kD spe-
cies. Since there is only one potential N-linked glycosyla-
tion site in the predicted protein, and complete removal of
N-linked glycosylation reduces both ITM2A species to a
single band, the difference in size between the 45 and the
43 kD species must be due to differential N-linked glyco-
sylation. Since the single predicted N-linked glycosylation
site is within the COOH-terminal domain, our data dem-
onstrating its use support the prediction that ITM2A is a
type II transmembrane protein.
Immunofluorescent Microscopy of EL4 Cells Reveals Hetero-
geneous Expression and Subcellular Distribution of ITM2A. To
determine the subcellular localization of ITM2A protein, we
performed immunofluorescent microscopy of two thymoma
cell lines, EL4 and AKR1010, using the affinity-purified
anti-ITM2A antiserum. A positive signal was detected in
EL4 cells (Fig. 7, A and D), which express endogenous
ITM2A, but not in AKR1010 cells (Fig. 7 B), which do
not express ITM2A. No signal was seen in EL4 when anti-
ITM2A antiserum was replaced by preimmune serum or
Figure 5. Northern blot anal-
ysis for ITM2A expression in
thymocytes from RAG-22/2
mice which were injected with
PBS (R), or anti-CD3e Ab and
harvested 16 h later (R12C11),
and from control C57BL/6 mice
(B6). The blot was successively
hybridized, stripped, and rehy-
bridized with probes for ITM2A
and EF1a.
Figure 6. Identification of
ITM2A protein. (A) Immunoblot
analysis of purified GST and
lysates from EL4 cells or EL4
transfected with NmycITM2A.
Samples of purified GST (20 ng),
EL4 lysate (100 mg), and EL41
NmycITM2A lysate (100 mg)
were run on denaturing 10%
polyacrylamide 6-cm gels, trans-
ferred to membrane, and used for
immunoblot analysis with affin-
ity-purified anti-ITM2A antise-
rum (left panel) or anti–human
c-myc Ab (9E10; right panel). (B)
Immunoblot analysis of lysates
from EL4, EL41NmycITM2A
(Nmyc), or AKR1010 (1010).
100  mg of each lysate was run on
a denaturing 10% polyacrylamide
20-cm gel, transferred to mem-
brane, and used for immunoblot analysis with affinity-purified anti-ITM2A
antiserum. (C) Deglycosylation of EL4 lysates. Lysates from EL4 cells were
denatured and then treated with EndoH (EndoH 1) or N-glycosidase F (N
Gly 1), incubated in mock reactions (EndoH 2 and N Gly 2, respec-
tively), or left untreated (U).223 Kirchner and Bevan
normal rabbit IgG (Fig. 7 C). The expression of ITM2A in
EL4 was heterogeneous, both in amount and subcellular
localization. ITM2A staining in EL4 ranged from undetect-
able to very bright. In the majority of cells in which pro-
tein was detected, ITM2A appeared to localize primarily to
large cytoplasmic vesicles, possibly endosomes, and a large
perinuclear structure, presumably the Golgi apparatus. In
some cells, ITM2A seemed to localize to the plasma mem-
brane, as indicated by a characteristic ring pattern (Fig. 7 A,
arrows). ITM2A was not detected in the nucleus. Immu-
nofluorescent microscopy of EL41NmycITM2A using the
anti-myc Ab gave a pattern identical to that seen in EL4
cells with anti-ITM2A antiserum (data not shown). In these
cells, the myc-tagged version of ITM2A was expressed
from a heterologous promoter (the retroviral LTR) which
should be active in all of the retrovirally transduced cells.
This suggests that the heterogeneous expression of ITM2A
protein among individual cells may be regulated at the
translational or posttranslational level, rather than at the
transcriptional level. Therefore, ITM2A expression may be
regulated at several points.
Experiments described above indicated that ITM2A was
induced by activation. Although the endogenous level of
ITM2A transcript in EL4 cells was comparable to that in a
C57BL/6 thymus (data not shown), given the heterogene-
ity of expression observed at the protein level it was of in-
terest to determine what would happen to the amount and
subcellular localization of ITM2A protein upon activation.
EL4 cells were cultured in medium supplemented with
PMA and ionomycin for 24 h, then analyzed by immuno-
fluorescent microscopy (Fig. 7 D). After activation, virtually
every cell had detectable levels of ITM2A (although there
was still a wide range of expression) and, surprisingly, ITM2A
appeared to localize to the plasma membrane in almost all of
the cells. This apparent change in localization could be due
to increased trafficking of existing intracellular stores of
ITM2A to the cell surface, increased expression, or both.
Based on the overall intensity of the ITM2A signal ob-
served in immunofluorescent microscopy (Fig. 7 D) and in
immunoblot analysis of cell lysates (data not shown), there
was a significant increase in the amount of ITM2A protein
produced in EL4 cells after activation which correlated with
the increase in transcription (Fig. 4). However, we observed
many cells after activation that had the characteristic ring
pattern but only low ITM2A protein levels, suggesting that
an increase in the amount of protein alone was not suffi-
cient to explain the apparent increase in plasma mem-
brane–associated protein.
We also examined the subcellular localization of ITM2A
in thymocytes and lymph node cells from C57BL/6 and
RAG-22/2OT-1 mice (data not shown). The proportion
of cells expressing ITM2A protein in these samples corre-
lated with the relative level of transcription (Fig. 1 C and
Fig. 3), with a higher percentage of expressing cells in RAG-
22/2OT-1 thymocytes (z18%) compared with C57BL/6
thymocytes (z6%), and a higher percentage of expressing
thymocytes compared with lymph node cells of either strain.
The pattern of subcellular localization in thymocytes was
similar to that in EL4 cells, with most cells exhibiting
vesicular and perinuclear staining. Cells with bright charac-
teristic ring patterns were observed only rarely, even in
RAG-22/2OT-1 thymocytes, suggesting that the number
of thymocytes with plasma membrane expression of ITM2A
at any one time was quite low.
ITM2A Is Expressed on the Cell Surface. Although the ring
patterns observed by immunofluorescent microscopy of EL4
cells, particularly after activation, suggested that at least a
portion of ITM2A was expressed on the cell surface, the
small size of the cytoplasm in these cells and the resolution
of confocal microscopy made it impossible to tell if this was
the case. To determine if ITM2A was expressed on the cell
surface, we biotinylated EL4 cells at 48C (to prevent endo-
cytosis), then lysed the cells and precipitated the biotiny-
lated proteins with streptavidin-agarose. Both the bound
material and the unbound material were analyzed by SDS-
PAGE and immunoblot analysis with anti-ITM2A anti-
serum and antiactin Ab (Fig. 8). Lysates of nonbiotinylated
EL4 cells were precipitated and analyzed in the same man-
ner. ITM2A was detected in both the bound and unbound
fractions from surface biotinylated EL4 cells, but only in
the unbound fraction from control cells. To control for in-
tracellular protein in the bound fraction, the blots were
stripped and reprobed with antiactin Ab. Actin was readily
detected in the unbound fractions, but not in the precipi-
tate, from both biotinylated and nonbiotinylated cells. Ad-
dition of increasing amounts of streptavidin-agarose to bio-
Figure 7. Subcellular localiza-
tion of ITM2A. Immunofluores-
cent microscopy of EL4 cells (A,
C, and D) or AKR1010 cells
(B) with affinity-purified anti-
ITM2A antiserum (A, B, and D)
or normal rabbit IgG (C). Cells
in D were activated by culturing
for 24 h in medium supple-
mented with 1.2 ng/ml PMA
and 250 ng/ml ionomycin. The
top panel in each portion of the
figure is the fluorescent image,
and the bottom panel is the
phase image of the same cells.224 A Novel T Cell Activation Marker
tinylated EL4 cell lysates failed to precipitate more ITM2A
(data not shown). Assuming the biotinylation reaction was
complete, we estimate the fraction of cell surface ITM2A
protein to be z4% of the total ITM2A protein in a popula-
tion of cells. Given the heterogeneous expression and sub-
cellular localization pattern of ITM2A, described above,
this fraction could be much higher in some cells. Our dem-
onstration of surface expression further supports the predic-
tion that ITM2A is a type II transmembrane protein.
Overexpression of ITM2A under Control of the lck Proximal
Promoter in Mice Causes Downregulation of CD8 in DP Thy-
mocytes. ITM2A transcription in the thymus appears to be
tightly regulated, occurring at significant levels at only cer-
tain developmental stages. To determine if overexpression of
ITM2A would perturb thymocyte development, we gener-
ated transgenic mice which expressed ITM2A under control
of the lck proximal promoter. Three founders (AM573,
AM712, and AM713) were bred to C57BL/6 mice. The
transgene transcript was distinguishable by size from the en-
dogenous message (Fig. 9 A). The transgenic progeny of all
three founders exhibited high levels of transgene expression
in both the thymus (Fig. 9 A) and spleen (data not shown)
relative to endogenous ITM2A. Immunoblot analysis of
thymocytes showed that the ITM2A protein was also ex-
pressed significantly higher in transgenic mice compared
with the littermate controls (data not shown).
Thymocytes from both transgenic and littermate control
mice were analyzed by three-color flow cytometry for ex-
pression of CD4, CD8, CD3, CD69, and HSA. The FACS®
plots shown in Fig. 9 B represent littermate control (left)
and transgenic mice (right) from the AM712 founder line.
Expression of ITM2A under the lck proximal promoter
had no significant effect on thymus cellularity (data not
shown). However, expression of the transgene correlated
significantly with a decrease in the mean surface levels of
CD8 on DP thymocytes (R6) and with a corresponding
increase in the percentage of CD41CD8lo cells (R3; Fig. 9,
B and C). The AM573 founder line exhibited the mildest
phenotype, with only a 1.6-fold increase in the mean per-
centage of CD41CD8lo thymocytes in transgenic mice, even
though expression of the transgene was much higher than
endogenous ITM2A. The AM712 and AM713 founder
lines, which had higher levels of transgene expression, ex-
hibited a 5.9- and 6.6-fold increase, respectively, in the
Figure 8. ITM2A is ex-
pressed on the cell surface. EL4
cells were surface biotinylated
(1biotin) or not (2biotin), then
lysed. The biotinylated proteins
in the cell lysate were precipi-
tated with streptavidin-agarose,
and both bound (B) and un-
bound (UB) fractions were ana-
lyzed by immunoblot analysis.
Blots were successively probed,
stripped, and reprobed with af-
finity-purified anti-ITM2A anti-
serum (top panel) and antiactin
Ab (bottom panel).
Figure 9. Expression of ITM2A in transgenic mice under control of
the lck proximal promoter. (A) Northern blot analysis of transgene ex-
pression. In the left panel, the samples were thymus RNA from C57BL/6
(B6) mice, or transgenic (Tg1) or littermate control (LM) mice from the
AM573 founder line. In the right panel, the samples were thymus RNA
from progeny of three founder lines: AM573, AM712, and AM713. (B)
Flow cytometry analysis of thymocytes from a littermate control (left) and
a transgenic mouse (right) of the AM712 founder line. The percentage of
total thymocytes (% Gated), CD8 mean fluorescence intensity (MFI), and
CD4 MFI for each gated region are shown below each plot. (C) Mean
values and SEM are shown for the CD8 MFI of DP thymocytes (R6) (left
panel) and the percentage of CD41CD8lo cells (R3) of total thymocytes
(right panel) from littermate control (light gray bars) and transgenic (dark
gray bars) mice. The number of mice analyzed (n) is shown below the bar
for each group. The significance of the difference between littermate
control and transgenic mice is shown for the AM573 and AM712 founder
lines (based on the Mann-Whitney U test, reference 42). (The n value for
each group in the AM713 founder line was too low to apply this test.)225 Kirchner and Bevan
mean percentage of CD41CD8lo cells relative to littermate
controls.
In T cell development, CD41CD8lo thymocytes are
transitional intermediates between immature DP cells and
mature SP cells and are capable of differentiating into either
the CD4 or CD8 lineage (13–15). They are characterized
by high cell surface expression of CD69 and CD5, inter-
mediate to high surface levels of TCR, and high intracellu-
lar levels of bcl-2 (12, 16, 17). However, flow cytometry
analysis of the CD41CD8lo cells (R3) from the transgenic
mice revealed that they had low levels of CD69 and CD3,
a surface phenotype similar to the majority of DP thy-
mocytes in a normal thymus (data not shown). Therefore,
the CD41CD8lo thymocytes of the transgenic mice did not
appear to be typical transitional cells and more closely re-
sembled DP cells which had simply downregulated their
surface level of CD8. It was possible that this population
was derived from DN thymocytes that exhibited delayed
expression of CD8 during differentiation into DP thy-
mocytes, rather than from DP cells which had downregu-
lated CD8. To address this, we performed kinetic analysis
of thymocyte differentiation in both transgenic and litter-
mate control mice by labeling with 5-bromo-29-deoxyuri-
dine (BrdU; data not shown). At 5 h after injection, z6%
of thymocytes were labeled and these consisted mainly of
DP cells. Importantly, there was no enrichment of
CD41CD8lo cells in the transgenic BrdU1 cells relative to
the littermate control. These data strongly suggest that the
CD41CD8lo population in the transgenic mice was derived
from DP cells upon CD8 downregulation.
Interestingly, this degree of CD8 downregulation was
not observed in either the CD8 SP thymocytes or the pe-
ripheral CD8 T cells of the transgenic mice, despite the fact
that the transgene was expressed at a much higher level
than endogenous ITM2A in splenocytes (data not shown).
Furthermore, transfection of AKR1010 cells with ITM2A
did not cause downregulation of their low level of CD8,
and expression of ITM2A was readily detected by RT-
PCR in other thymoma cell lines which have high surface
expression of CD8 (AKR.1 [38] and 1200M [39]; data not
shown). Therefore, the influence of ITM2A expression on
CD8 surface expression appeared to be specific to a partic-
ular stage in thymocyte development.
Discussion
Several molecules have been identified which are upreg-
ulated or downregulated during positive selection, but the
mechanism governing this process is still unclear. Using sub-
tractive hybridization between a thymus which has a high
degree of positive selection and a thymus which is blocked
at the immature DP stage, we have identified ITM2A as a
novel marker for T cell development. Like other markers of
T cell selection, e.g., CD69 and CD5, ITM2A appears to
be transcriptionally upregulated during the transition from
DP to SP thymocytes. This was observed in two ways: (a)
higher levels of ITM2A transcript were seen in a selecting
C57BL/6 or hyperselecting RAG-22/2OT-1 thymus com-
pared with a nonselecting RAG-22/2TAP-12/2OT-1 thy-
mus which is blocked at the DP stage of T cell develop-
ment; and (b) RT-PCR analysis of sorted thymocyte
subsets showed dramatically higher expression in the inter-
mediate CD41CD8loHSAhi cells compared with the DP
subset.
ITM2A was cloned from a thymus in which immature
DP cells developed predominantly into the CD8 lineage,
yet its expression appeared to be higher in the sorted CD4
SP subset compared with the CD8 SP subset. By analyzing
ITM2A expression in sorted mature CD41CD82HSAlo
and intermediate CD41CD8loHSAhi thymocytes, it was
determined that expression is significantly higher in the
CD41CD8loHSAhi population. The majority of thymo-
cytes in RAG-22/2OT-1 mice appear to be cells that are
intermediate between DP and mature SP. In these mice,
too, ITM2A message was found to be enriched in the
CD41CD8loHSAhi thymocytes (data not shown). Inclusion
of a portion of the CD41CD8loHSAhi intermediate cells in
the CD4 SP sorted subset cannot fully account for the
higher ITM2A expression compared with the CD8 SP
subset, since mature CD41CD82HSAlo cells also had more
message than CD8 SP cells. In contrast, RT-PCR analysis
of peripheral CD4 and CD8 T cells showed that ITM2A
was expressed at similar levels in these two populations, ar-
guing against a lineage-specific expression pattern. Higher
expression of ITM2A in mature CD41 thymocytes may re-
flect a unique requirement for ITM2A in these cells during
development, perhaps in regulating CD8 coreceptor ex-
pression. Alternatively, there may simply be a difference in
the rate of ITM2A downregulation as CD41CD8loHSAhi
intermediate thymocytes are selected into each lineage.
Given the lower level of message in the peripheral organs
compared with the thymus, ITM2A expression appears to
be downregulated not only during the differentiation of
CD41CD8loHSAhi intermediate cells into mature CD41
and CD81 thymocytes, but also during the final stages of
thymocyte maturation or emigration to the periphery.
The pattern of ITM2A expression in the sorted thy-
mocyte subsets correlated with upregulation during posi-
tive selection, but the higher expression in DP cells com-
pared with DN cells suggested that ITM2A expression
could be induced to a lesser extent earlier in thymocyte de-
velopment. The increased expression in RAG-22/2 thymo-
cytes upon cross-linking of CD3 confirmed this hypothesis,
demonstrating that ITM2A could be upregulated in DN
thymocytes. This increase was not due to expression from
DP cells, since the thymuses were harvested at 16 h after
stimulation, before differentiation into DP thymocytes (40).
Upregulation may occur in the DN cells of a normal thy-
mus upon signaling through the pre-TCR. ITM2A was re-
cently cloned by another group in a screen for genes which
are expressed in CD341 hematopoietic stem/progenitor
cells (41). Therefore, ITM2A may be involved at several
steps in T cell development.
Although ITM2A was detected at a much lower level in
peripheral organs compared with the thymus, its expression
in splenocytes was significantly increased by activation, either226 A Novel T Cell Activation Marker
by signaling through the TCR (with ConA or an MHC-
peptide ligand) or by directly activating protein kinase C
and increasing intracellular calcium (with PMA and iono-
mycin, data not shown). Activation with either a nonphys-
iological (ConA or PMA and ionomycin) or a physiologi-
cal (MHC-peptide ligand) signal resulted in steady state
levels of ITM2A transcription comparable to that in the
thymus. These data, together with the increased expression
in RAG-22/2 thymocytes upon CD3 cross-linking and in
CD4 SP cells compared with DP cells, demonstrate that
ITM2A transcription is induced or upregulated by signals
transmitted through the TCR/CD3, either in thymocytes
or mature T cells. Thus, we propose that ITM2A is a novel
activation marker, both in thymocyte development and pe-
ripheral T cell activation.
We present strong evidence that ITM2A is a type II trans-
membrane glycoprotein expressed on the cell surface. First,
using affinity-purified anti-ITM2A antiserum directed against
the first 52 aa of the protein, we showed that ITM2A exists
as two species, 45 and 43 kD, which appear to be differen-
tially glycosylated since removal of N-linked glycosylation
results in a single species of z39 kD. The demonstration of
N-linked glycosylation is consistent with the COOH-ter-
minal domain (in which the glycosylation site resides) being
extracellular. Second, immunofluorescent microscopy anal-
ysis of EL4 cells suggested that at least a fraction of ITM2A
protein is expressed on the cell surface, and detection of
ITM2A in the fraction of proteins precipitated with
streptavidin-agarose after cell surface biotinylation con-
firmed this. The amount of surface-expressed ITM2A in-
creased after activation with PMA and ionomycin. Our ex-
periments did not address whether this was due to a change
in trafficking or simply to an increase in the total amount of
ITM2A protein, but the expression of ITM2A clearly in-
creased with activation, at both the transcriptional level and
the protein level. Third, using the anti-ITM2A antiserum
we were unable to detect ITM2A by flow cytometry, even
with cells that gave surface staining in immunofluorescent
microscopy (data not shown). The likely explanation for
this result is that the NH2-terminal domain of ITM2A was
inaccessible due to being intracellular, consistent with a
type II transmembrane topology. CD69 is an activation-
induced type II transmembrane glycoprotein which exists
as a disulfide-linked homodimer of two differentially glyco-
sylated proteins both in mice and humans (in which it has
only one potential N-linked glycosylation site [33–36]). It
will be of interest to determine whether ITM2A, too,
forms a homodimer.
Transgenic mice which expressed the full-length wild-
type ITM2A cDNA under control of the lck promoter had
a much higher level of ITM2A compared with the litter-
mate controls in both the thymus (Fig. 9 A) and the spleen
(data not shown), at both the transcriptional level (Fig. 9 A)
and the protein level (data not shown). We found that
overexpression of ITM2A caused a partial downregulation of
the mean surface level of CD8 in DP thymocytes and a cor-
responding increase in the mean percentage of CD41CD8lo
cells (Fig. 9, B and C). However, the CD41CD8lo cells did
not express higher levels of either CD69 or TCR/CD3
compared with DP cells of a normal thymus and, thus, did
not appear to be normal transitional intermediates. Based
on kinetic studies using BrdU labeling, these transgenic
CD41CD8lo cells appear to be derived from DP cells upon
downregulation of surface CD8 rather than from DN cells
exhibiting delayed CD8 expression during differentiation
into DP cells (data not shown). One of the first steps in
positive selection of DP thymocytes to SP thymocytes is
the downregulation of both CD4 and CD8 coreceptors,
and CD8 downregulation starts before CD4 (10). Although
the effect of ITM2A overexpression could be aberrant, it is
tempting to speculate that ITM2A has a role in this early
step of positive selection. The same level of downregula-
tion in CD8 surface levels was not observed in either ma-
ture CD8 SP thymocytes or peripheral CD8 T cells. This
could be due to the lower level of transgene expression in
splenocytes compared with thymocytes, although it was
significantly higher than the endogenous ITM2A expres-
sion. Alternatively, the effect of the transgene expression
could be context dependent, occurring only at a particular
stage of T cell development.
In addition, we noted a slight increase in the ratio of
CD4 to CD8 cells in the transgenic mice, in both the ma-
ture thymocyte subsets (R1/R2) and the peripheral T cells
(data not shown). The lower surface level of CD8 in the
DP thymocytes of the transgenic mice could affect the
CD4/CD8 ratio by decreasing the overall affinity of the in-
teraction of TCR with selecting MHC class I–peptide
ligands. Positive selection of MHC class I–restricted T cells
in the absence of CD8 coreceptor was increased by addi-
tion of an MHC–peptide complex for which the TCR has
a greater affinity (29). Perhaps the decreased surface level of
CD8 in the transgenic DP thymocytes causes a sufficient
decrease in the affinity of MHC class I–restricted TCR–
ligand interactions such that a fraction of DP cells which
would have been selected instead die by neglect.
Given that ITM2A appears to be developmentally regu-
lated in two different systems, chondro/osteogenesis and T
cell development, it is worth speculating what common
role it might play. If the role of ITM2A in thymocyte de-
velopment is to alter the surface level of coreceptor, per-
haps it also has a role in regulating expression of molecules
which contribute to the affinity of interactions between de-
veloping chondrocytes or osteocytes with their stromal ele-
ments, and the resulting intracellular signaling. Further ex-
periments that directly address the role of ITM2A in a
normal thymus and in developing chondro/osteocytes will
need to be done.
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